C - Chemistry – Metallurgy – 07 – D
Patent
C - Chemistry, Metallurgy
07
D
C07D 401/12 (2006.01) A61K 31/4545 (2006.01) A61K 31/496 (2006.01) A61K 31/5377 (2006.01) A61K 31/549 (2006.01) A61K 31/554 (2006.01) A61P 1/04 (2006.01) A61P 1/16 (2006.01) A61P 9/00 (2006.01) A61P 11/02 (2006.01) A61P 11/06 (2006.01) A61P 13/12 (2006.01) A61P 17/06 (2006.01) A61P 19/02 (2006.01) A61P 25/00 (2006.01) A61P 27/02 (2006.01) A61P 29/00 (2006.01) A61P 31/00 (2006.01) A61P 31/12 (2006.01) A61P 31/18 (2006.01) A61P 37/00 (2006.01) A61P 37/06 (2006.01) A61P 37/08 (2006.01) A61P 43/00 (2006.01) C07
Patent
CA 2644368
Disclosed is a compound represented by the general formula (I), a salt or N-oxide of the compound, a solvate of the compound, salt or N-oxide, or a prodrug of the compound, salt, N-oxide or solvate, which can bind specifically to CCR5 and therefore is useful for the prevention and/or treatment of a CCR5-associated disease, such as an inflammatory disease (e.g., asthma, nephritis, nephropathia, hepatitis, arthritis, rheumatoid arthritis, rhinitis, conjunctivitis, ulcerative colitis), an immune-mediated disease (e.g., autoimmune disease, rejection after organ transplantation, immunosuppression, psoriasis, multiple sclerosis), an infectious disease (e.g., infection with human immunodeficiency virus, acquired immunodeficiency syndrome), an allergic disease (e.g., atopic dermatitis, urticaria, allergic bronchopulmonary aspergillosis, allergic eosinophilic gastroenteritis), suppression of ischemia-reperfusion injury, acute respiratory syndrome, shock associated with a bacterial infection, diabetes, cancer metastasis or the like. (I) wherein each symbol is as defined in the description.
La présente invention concerne un composé représenté par la formule générale (I), un sel ou N-oxyde du composé, un solvate du composé, un sel ou N-oxyde, ou un promédicament du composé, un sel, N-oxyde ou solvate, qui peut se lier spécifiquement à CCR5 et est à ce titre utile pour la prévention et/ou le traitement d'une maladie associée à CCR5, telle qu'une maladie inflammatoire (p. ex., l'asthme, la néphrite, la néphropathie, l'hépatite, l'arthrite, la polyarthrite rhumatoïde, la rhinite, la conjonctivite, la colite ulcéreuse), une maladie immunitaire(p.ex., maladie autoimmune, rejet après greffe d'organe, immunosuppression, psoriasis, sclérose en plaques), une maladie infectieuse (p. ex., infection par le virus de l'immunodéficience humaine, syndrome de l'immunodéficience acquise), une maladie allergique (p. ex., dermatite atopique, urticaire, aspergillose bronchopulmonaire allergique, gastroentérite éosinophile allergique), suppression d'une lésion induite par une ischémie-reperfusion, syndrome respiratoire aigu, choc associé à une infection bactérienne, diabète, métastases cancéreuses ou analogues. (I) où chaque symbole est tel que défini dans la description.
Hashimura Kazuya
Kusuda Shinya
Nishiyama Toshihiko
Shibayama Shiro
Ueda Junya
Ono Pharmaceutical Co. Ltd.
Riches Mckenzie & Herbert Llp
LandOfFree
Nitrogenated heterocyclic derivative, and pharmaceutical... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Nitrogenated heterocyclic derivative, and pharmaceutical..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Nitrogenated heterocyclic derivative, and pharmaceutical... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1967216